Several population studies have demonstrated an increased risk of CKD in patients with metabolic-associated steatotic liver disease (MASLD).3, –5 Moreover, the polymorphism in the patatin-like phospholipase domain-containing protein 3 that is responsible for the development of hepatic steatosis in humans has also been linked to the development of CKD in adults and children.6, –8 These observations demonstrate that the liver influences kidney function without overt signs of liver disease such as advanced cirrhosis. This evidence concerns the gene PNPLA3 and chronic kidney disease.